Drug profile · INN
risedronate sodium
RISEDRONATE SODIUM
risedronate sodium (RISEDRONATE SODIUM) is a farnesyl diphosphate synthase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — risedronate sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 2
- Data quality
- 0.89
Quick answer
risedronate sodium (RISEDRONATE SODIUM) is a farnesyl diphosphate synthase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Farnesyl diphosphate synthase inhibitor
Primary target: Farnesyl pyrophosphate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is risedronate sodium?
risedronate sodium (RISEDRONATE SODIUM) is a farnesyl diphosphate synthase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for risedronate sodium?
RISEDRONATE SODIUM is a marketed brand name for risedronate sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of risedronate sodium?
risedronate sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.